BMEYE Launches a Noninvasive, Breakthrough Parameter for Delivery of Oxygen (DO2I) and new Fluid Management Parameters at the European Society of Anesthesia Congress

By Bmeye B.v., PRNE
Monday, June 13, 2011

AMSTERDAM, June 14, 2011 -

- New Algorithms Offered in ccNexfin
Combined With Noninvasive Beat-to-beat Cardiac
(CO), Blood Pressure (BP)
and Masimos Breakthrough
Noninvasive Hemoglobin
(SpHb) and Oxygen
(SpO2) Measurements  

BMEYE B.V., the inventor of noninvasive, beat-to-beat cardiac
output and blood pressure monitoring, announces the launch of DO2I
- the delivery of oxygen to the tissues. DO2I is the multiple of
cardiac output, oxygen saturation and hemoglobin and is a critical
parameter for clinicians. This new parameter is made available
noninvasively for the first time by the combination of two
innovative technologies: the BMEYE Nexfin CO-TREK for noninvasive
and continuous cardiac output monitoring and the Masimo Rainbow SET
for noninvasive and continuous hemoglobin and oxygen saturation
monitoring. In addition BMEYE launched two new parameters, Pulse
Pressure Variation (PPV) and Stroke Volume Variation  (SVV),
which are essential for monitoring of the fluid responsiveness
status of the patient. All variables provided are real-time,
beat-to-beat measurements of hemodynamic parameters, which enable
clinicians to detect impending hemodynamic crisis and optimize
treatment before tissue hypoxia and organ injury ensues in
peri-operative period and in critical care.  

Hemodynamic monitoring has traditionally relied upon invasive,
costly, intermittent, or unreliable methods to assist clinicians in
maintaining adequate oxygen delivery, tissue perfusion and to
prevent hypoxia and its irreversible damage. However, the ccNexfin
with Masimo Rainbow SET offers a totally noninvasive method of
providing some of the most advanced cardiovascular and hemodynamic
monitoring capabilities available today.  It utilizes a BMEYE
finger cuff to capture and continuously measure beat-to-beat blood
pressure, mean arterial pressure (MAP), cardiac output (CO), stroke
volume (SV), systemic vascular resistance (SVR), dynamic fluid
responsiveness parameters (PPV, SVV), index of contractility
(dP/dt) and a Masimo finger sensor to noninvasively and
continuously measure hemoglobin (SpHb®), oxygen saturation
(SpO2), and perfusion index (PI). The combined
technologies provide the unique parameter oxygen delivery

 These integrated functional hemodynamic monitoring data
allow clinicians to predict and proactively address the early signs
of hemodynamic instability during the peri-operative period and in
critical situations.

“With the integration of PPV and SVV we further strengthen our
ccNexfin product offering, with the addition of DO2I we take
hemodynamic monitoring to the next level” stated Rob de Ree, CEO of
BMEYE.  ”We are proud to be the first company to provide this
parameter to the clinic and combined with the available parameters
in the ccNexfin to have the potential to provide earlier diagnosis
and early goal-directed therapies in anesthesia and emergency care
to improve patient care while reducing costs.”

Prof. Azriel Perel from the Tel Aviv University stated: “For me
personally it is a dream come true. For the first time we have a
totally noninvasive advanced hemodynamic monitor which can provide
us with continuous DO2I within minutes without the complications
that are associated with traditional invasive techniques. This is a
great step forward in the management of patients in the operating
room and the intensive care unit. I believe that by making s
 DO2I and fluid  responsiveness parameters available
noninvasively, in addition to cardiac output and blood pressure the
ccNexfin has the potential to change medical practice in the
peri-operative setting.”  


BMEYE, a Dutch company based in Amsterdam, The Netherlands,
develops innovative medical devices with broad application in
clinical settings that require cardiovascular monitoring.
Specifically, BMEYE produces patient monitors that noninvasively
measure continuous blood pressure and cardiac output. BMEYE’s
mission: BMEYE is the premier provider and will set the standard of
noninvasive, beat-to-beat, user-friendly cardiovascular monitoring
systems, to improve patient care and reduce healthcare costs.

Rob de Ree, BMEYE B.V., +31-207512410

will not be displayed